Abstract
Besides bioequivalence, the crucial assumption of equal health benefits of generics and brand-name cardiovascular drugs is based upon a single meta-analyses, published in 2008, combining only efficacy outcomes, and basing its conclusions on antiplatelet agents, ACE inhibitors and statins upon 50, 23 and 71 subjects, respectively. Such a scarcity of randomized evidence is typically used to support periodic claims of a superior clinical effect of brand-name vs generic drugs.We performed a meta-analysis to compare the efficacy and safety of generic versus brand-name cardiovascular drugs.
Lingua originale | English |
---|---|
pagine (da-a) | 74-74 |
Numero di pagine | 1 |
Rivista | European Journal of Public Health |
Volume | 25 |
Stato di pubblicazione | Pubblicato - 2015 |
Evento | 8th European Public Health Conference - Milano Durata: 14 ott 2015 → 17 ott 2015 |
Keywords
- cardiovascular diseases
- meta-analysis